HUTCHMED (China) Limited (LON:HCM - Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 239.06 ($3.19) and traded as low as GBX 202.44 ($2.70). HUTCHMED shares last traded at GBX 206 ($2.75), with a volume of 26,863 shares changing hands.
HUTCHMED Price Performance
The company has a current ratio of 2.81, a quick ratio of 2.97 and a debt-to-equity ratio of 11.97. The company has a 50 day moving average of GBX 221.99 and a 200-day moving average of GBX 239.06. The firm has a market capitalization of £2.19 billion, a P/E ratio of -51.56 and a beta of 0.76.
About HUTCHMED
(
Get Free Report)
We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.
We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.
HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
